4BIO Capital intends to take gene and cell therapies mainstream
Category: #health  By Paroma Bhattacharya  Date: 2019-09-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

4BIO Capital intends to take gene and cell therapies mainstream

The venture capitalist firm has secured an investment of $50 million and is expecting to gather an investment of up to $150 million till 2020.

4BIO Capital, a London-based firm investing in Public Equities in Life Sciences and Venture Capital, has made headlines for raising $50 million (€45 million) to finance advanced therapy startups. The leading venture capital firm intends to invest the money, with an additional $100 million which it expects to add by the final close, into those firms that are focused on extending the use of improved therapies to critical diseases such as rheumatoid arthritis and diabetes.

As per reports, 4BIO has secured the $50 million commitment, involving a cornerstone investment from Children’s Minnesota, a U.S pediatric hospital, for its next advanced therapy VC fund accompanied by the previous successful investments in companies like Orchard Therapeutics. Currently, the firm aims to improve the advanced therapy sector and wants to demonstrate efficiency in critical diseases. 

Speaking on the move, Dmitry Kuzmin, Managing Partner, 4BIO, said that the company is focused on evolving advanced therapies from their historical stage of monogenic genetic disorders and super-rare diseases to a larger, more publicly significant indications where the firm openly has thousands of patients. 

Reportedly, a string of milestone gene and cell therapy approvals have turned the firm’s perceptions, allowing it to research on major diseases and appeal the investment needed to bankroll their elaborate strategy. 

According to Kuzmin, the company is delighted by the level of interest it has gained and is now witnessing a considerable growth of interest in Institutional investors.

Moreover, that interest has resulted in commitments of above $50 million. The company eventually expects to have an investment of $150 million until it holds the final close of the fund in the Q3&4 of 2020.

Additionally, the company will put the investment in developers of gene and cell therapies, targeted treatments, the microbiome and RNA-based candidates, with a quarter of the money going to the firms created by 4BIO itself.

Source Credit: https://www.fiercebiotech.com/biotech/4bio-raises-vc-fund-to-take-cell-and-gene-therapies-mainstream



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
Mirati Therapeutics reveals Phase ½ results of KRAS inhibitor therapy
By Paroma Bhattacharya

Mirati Therapeutics, an oncology company that engages in the development of targeted therapies, recently released its clinical trial results for MRTX849. Reportedly, MRTX849 is a KRAS G12C inhibitor and the data from P...

Best Buy to offer free next-day delivery feature on various products
Best Buy to offer free next-day delivery feature on various products
By Paroma Bhattacharya

Online retailers are always launching new and attractive deals during the holiday season, as it grosses the highest sale time for the year. Several retailer rollout out attractive offers, such as discounts or complimen...

Nature Tech Corp partners with Aldevron for gene therapy manufacturing
Nature Tech Corp partners with Aldevron for gene therapy manufacturing
By Paroma Bhattacharya

The global cell and gene therapy sector is expected to witness a thriving period of growth over the forthcoming years. In fact, owing to the favorable growth conditions across the industry, numerous biotechnology and p...